Brief: Alector Achieves Target Enrollment in the INFRONT-3 Phase 3 Clinical Trial of Latozinemab

Alector

27/10/2023 12:05

Oct 27 (Reuters) - Alector Inc  ALEC.O :
    * ALECTOR ANNOUNCES ACHIEVEMENT OF TARGET ENROLLMENT IN THE
PIVOTAL INFRONT-3 PHASE 3 CLINICAL TRIAL OF LATOZINEMAB IN
INDIVIDUALS WITH FRONTOTEMPORAL DEMENTIA DUE TO A PROGRANULIN
GENE MUTATION (FTD-GRN)
    * ALECTOR INC - 101 SYMPTOMATIC FTD-GRN PARTICIPANTS
ENROLLED IN
INFRONT-3

Source text for Eikon:  ID:nGNX8XdKvD 
Further company coverage:  ALEC.O 

 ((Reuters.Briefs@thomsonreuters.com;))